SCHEMBL30746484

SCHEMBL30746484

Cc1c(Oc2ccc(Cl)cc2)cncc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 4/20 0.40
PTGS2 P35354 4/20 0.40
CDK8 P49336 11/20 0.39
CCNC P24863 10/20 0.39
PIM1 P11309 2/20 0.38
MAP4K2 Q12851 2/20 0.38
MAP2K2 P36507 1/20 0.38
ICAM1 P05362 4/20 0.37
SELE P16581 4/20 0.37
VCAM1 P19320 3/20 0.37
CCNT1 O60563 1/20 0.37
CDK9 P50750 1/20 0.37
LIPE Q05469 2/20 0.37
UCHL1 P09936 1/20 0.35
LTA4H P09960 1/20 0.34
DYRK3 O43781 1/20 0.34
MAP4K4 O95819 1/20 0.34
CDK1 P06493 1/20 0.34
RET P07949 1/20 0.34
CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26985737 1.00 PTGS1 (0.40) PTGS1PTGS2CDK8CCNCPIM1
SCHEMBL26985854 0.85 SLC6A4 (0.38) LIPEUCHL1
SCHEMBL26985696 0.84 LIPE (0.39) PTGS1PTGS2LIPE
SCHEMBL30746565 0.84 LIPE (0.39) PTGS1PTGS2LIPE
SCHEMBL30746595 0.84 CDK8 (0.40) PTGS1PTGS2CDK8CCNCPIM1
SCHEMBL26985460 0.84 CDK8 (0.40) PTGS1PTGS2CDK8CCNCPIM1
SCHEMBL26985444 0.82 SLC6A2 (0.37) PTGS1PTGS2ICAM1SELELIPE
SCHEMBL30746489 0.81 HTT (0.38) UCHL1
SCHEMBL26985465 0.81 HTT (0.38) UCHL1
SCHEMBL30746551 0.79 SLC22A12 (0.34) PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 US disclosed
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 US disclosed
EP-4551558-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS Nested Therapeutics, Inc. (US) 2025-05-14 EP disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK6, MAPK3, MAPK1 PTGS1 1888/4885PTGS2 1634/4885CDK8 259/4885
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS BRAF, MAP3K1, MAP3K5 PTGS1 1454/4885PTGS2 2096/4885CDK8 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.